Philadelphia Biotech Integral Molecular Celebrates 20 Years of Innovation, Growth, and Community

News provided by

Oct 12, 2021, 07:38 ET

PHILADELPHIA, Oct. 12, 2021 /PRNewswire/ -- Integral Molecular, a founding member of Philadelphia's biotech community, celebrates its 20th anniversary as a leader in antibody discovery and virology. With a mission to develop and apply innovative technologies that advance therapeutic discovery, the company has recently been at the forefront of Pennsylvania's contribution to the fight against COVID-19.

Integral Molecular celebrates 20 years of innovation. Pictured left to right, Joseph Rucker, PhD, VP of Research and Development, Sharon Willis, PhD, VP of Sales and Customer Relations, Philadelphia Mayor, Jim Kenney, Benjamin Doranz, PhD, MBA, President and CEO and Ross Chambers, PhD, VP of Antibody Discovery

"Integral Molecular is a long-time leader of Philadelphia's biotech community and we are thrilled to see the company's continued progress and expansion in our city," said Philadelphia Mayor Jim Kenney while celebrating this milestone. He additionally applauded the company's hard work and contribution to vaccine research.

Integral Molecular was co-founded by Drs. Benjamin Doranz, Sharon Willis and Joseph Rucker who share a long history that began as trainees at the University of Pennsylvania. Still working together, they steer the company into its third decade and actively shape its scientific direction.

"We started the company with a few interesting ideas and a small incubator space at the University City Science Center in Philadelphia," said Benjamin Doranz, CEO of Integral Molecular. Twenty years later, we are just as passionate about science and creating solutions, but now with the creativity of a larger team and over 400 customers around the world."

"Integral Molecular is proudly committed to the local community," said Sharon Willis, Vice-President. "We have an outstanding team of dedicated people with a desire to make a difference, and cultivate the next generation of scientists, including many from our immediate neighborhood." Integral Molecular works with students, artists, and workforce development initiatives in West Philadelphia. This includes the University City Science Center's BioArt residency program, BULB lab basics program, FirstHand STEM program, and Wistar Institute's Biomedical Technician Training Program.

With two research facilities in University City, Integral Molecular is actively planning its next expansion in Philadelphia's uCity Square.

About Integral Molecular
Integral Molecular (integralmolecular.com) is the industry leader in developing and applying innovative technologies that advance the discovery of therapeutics against difficult protein targets. With 20 years of experience focused on membrane proteins and antibodies, Integral Molecular's technologies have been integrated into the drug discovery pipelines of over 400 biotech and pharmaceutical companies to help discover new therapies for cancer, diabetes, autoimmune disorders and viral threats such as SARS-CoV-2, Ebola, Zika, and dengue viruses.

Press Contact:
Integral Molecular, Inc.
Soma Banik, PhD, Director of Communications
215-966-6061
[email protected]
www.integralmolecular.com

SOURCE Integral Molecular